메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 19, 2009, Pages 3073-3076
Phase II Trials in Journal of Clinical Oncology
Author keywords

[No Author keywords available]
Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; ANTINEOPLASTIC AGENT;
EID: 67650302854     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.1811     Document Type: Editorial
Times cited : (89)
References (11)
  • 1
    • 4344645978 scopus 로고    scopus 로고
    • Can the pharmaceutical industry reduce attrition rates?
    • Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, 2004
    • (2004) Nat Rev Drug Discov , vol.3 , pp. 711-715
    • Kola, I.1    Landis, J.2
  • 2
    • 2442715437 scopus 로고    scopus 로고
    • The ethics of early stopping rules: Who is protecting whom?
    • Cannistra SA: The ethics of early stopping rules: Who is protecting whom? J Clin Oncol 22:1542-1545, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1542-1545
    • Cannistra, S.A.1
  • 3
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    • Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 2505-2512
    • Ratain, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 4
    • 0035154256 scopus 로고    scopus 로고
    • Clinical trial designs for cytostatic agents: Are new approaches needed?
    • Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 265-272
    • Korn, E.L.1    Arbuck, S.G.2    Pluda, J.M.3
  • 5
    • 27244436755 scopus 로고    scopus 로고
    • Design issues of randomized phase II trials and a proposal for phase II screening trials
    • Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 7199-7206
    • Rubinstein, L.V.1    Korn, E.L.2    Freidlin, B.3
  • 6
    • 57849154374 scopus 로고    scopus 로고
    • Optimising the design of phase II oncology trials: The importance of randomisation
    • Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 45:275-280, 2009
    • (2009) Eur J Cancer , vol.45 , pp. 275-280
    • Ratain, M.J.1    Sargent, D.J.2
  • 7
    • 15744381413 scopus 로고    scopus 로고
    • Randomized phase II trials: What does randomization gain?
    • Wieand HS: Randomized phase II trials: What does randomization gain? J Clin Oncol 23:1794-1795, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 1794-1795
    • Wieand, H.S.1
  • 8
    • 49649127657 scopus 로고    scopus 로고
    • Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Engelman JA, Janne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clinical Cancer Res 14:2895-2899, 2008
    • (2008) Clinical Cancer Res , vol.14 , pp. 2895-2899
    • Engelman, J.A.1    Janne, P.A.2
  • 9
    • 15744374441 scopus 로고    scopus 로고
    • Clinical trial designs for predictive marker validation in cancer treatment trials
    • Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 2020-2027
    • Sargent, D.J.1    Conley, B.A.2    Allegra, C.3
  • 10
    • 49249111441 scopus 로고    scopus 로고
    • Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense?
    • Dodd LE, Korn EL, Freidlin B, et al: Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol 26:3791-3796, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3791-3796
    • Dodd, L.E.1    Korn, E.L.2    Freidlin, B.3
  • 11
    • 9444255722 scopus 로고    scopus 로고
    • Improving the quality of reporting of randomized controlled trials: The CONSORT statement
    • Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
    • (1996) JAMA , vol.276 , pp. 637-639
    • Begg, C.1    Cho, M.2    Eastwood, S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.